电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Queuine tRNA-Ribosyltransferase Domain Containing 1 (QTRTD1) (C-Term) Peptide

QTRTD1 适用: 人, 小鼠 宿主: 合成 BP, WB
产品编号 ABIN982522
发货至: 中国

Quick Overview for Queuine tRNA-Ribosyltransferase Domain Containing 1 (QTRTD1) (C-Term) Peptide (ABIN982522)

抗原

QTRTD1 (Queuine tRNA-Ribosyltransferase Domain Containing 1 (QTRTD1))

宿主

人, 小鼠

资源

  • 3
合成

应用范围

Blocking Peptide (BP), Western Blotting (WB)
  • 蛋白结构域

    C-Term

    序列

    DLTNTSRFYD RNDIEKEGIK YIKLQCKGHG ECPTTENTET FIRLCERFNE

    产品特性

    This is a synthetic peptide designed for use in combination with anti-Rngtt Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    纯化方法

    Purified
  • 应用备注

    Each Investigator should determine their own optimal working dilution for specific applications.

    限制

    仅限研究用
  • 状态

    Lyophilized

    溶解方式

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    浓度

    1 mg/mL

    缓冲液

    Final peptide concentration is 1 mg/mL in PBS.

    注意事项

    Avoid repeated freeze-thaw cycles.

    储存条件

    -20 °C

    储存方法

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • 抗原

    QTRTD1 (Queuine tRNA-Ribosyltransferase Domain Containing 1 (QTRTD1))

    背景

    Rngtt is a bifunctional mRNA-capping enzyme exhibiting RNA 5'-triphosphatase activity in the N-terminal part and mRNA guanylyltransferase activity in the C-terminal part. It catalyzes the first two steps of cap formation: by removing the gamma-phosphate from the 5'-triphosphate end of nascent mRNA to yield a diphosphate end, and by transferring the gmp moiety of GTP to the 5'-diphosphate terminus.

    Alias Symbols: AU020997

    Protein Size: 597

    分子量

    69 kDa

    基因ID

    24018

    NCBI登录号

    NM_011884, NP_036014

    UniProt

    O55236
You are here:
Chat with us!